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We compared the cost-benefit of two algorithms, recently proposed by the Centers for Disease Control and Prevention, USA,
with the conventional one, the most appropriate for the diagnosis of hepatitis C virus (HCV) infection in the Brazilian population.
Serum samples were obtained from 517 ELISA-positive or -inconclusive blood donors who had returned to Fundação Pró-
Sangue/Hemocentro de São Paulo to confirm previous results. Algorithm A was based on signal-to-cut-off (s/co) ratio of ELISA
anti-HCV samples that show s/co ratio ≥95% concordance with immunoblot (IB) positivity. For algorithm B, reflex nucleic acid
amplification testing by PCR was required for ELISA-positive or -inconclusive samples and IB for PCR-negative samples. For
algorithm C, all positive or inconclusive ELISA samples were submitted to IB. We observed a similar rate of positive results with
the three algorithms: 287, 287, and 285 for A, B, and C, respectively, and 283 were concordant with one another. Indeterminate
results from algorithms A and C were elucidated by PCR (expanded algorithm) which detected two more positive samples. The
estimated cost of algorithms A and B was US$21,299.39 and US$32,397.40, respectively, which were 43.5 and 14.0% more
economic than C (US$37,673.79). The cost can vary according to the technique used. We conclude that both algorithms A and
B are suitable for diagnosing HCV infection in the Brazilian population. Furthermore, algorithm A is the more practical and
economical one since it requires supplemental tests for only 54% of the samples. Algorithm B provides early information about
the presence of viremia.
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Introduction
In 1989 the Food and Drug Administration (FDA, USA)
licensed the first antibody detection test for hepatitis C
virus (HCV) using the c100-3 protein as antigen (1,2).
Since then new generations of anti-HCV tests have been
introduced for laboratory diagnosis and these have been
widely used in the serological screening of infected symp-
tomatic or asymptomatic individuals. Currently, second- or
third-generation enzyme-linked immunosorbent assays
(ELISA) are commercially available. These tests detect
antibodies against one or more of the several recombinant
or synthetic peptides produced by genes from different
regions of the HCV genome. The first-generation tests
detect antibodies with a sensitivity of 70 to 80% when
applied to populations with a high prevalence of HCV
infection, presenting an immunological window of 4 to 6
months (3). The second- and third-generation tests have a
high sensitivity of ~99.8% and an immunological window
reduced to approximately 10 weeks when compared to the
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first-generation tests (4). However, these tests yield a high
frequency of false-positive results, mainly in low-risk popu-
lations such as blood donors (5-7). Therefore, supplemen-
tal tests are required to ensure a reliable diagnosis.
The Centers for Disease Control and Prevention (CDC,
Atlanta, GA, USA) have recommended that no individual
be considered an HCV carrier until all positive results
obtained by screening tests are confirmed by more specific
tests, such as immunoblot (IB) (8). However, since the IB
test uses the same antigens as the screening test it has
limited value as a confirmatory test and is therefore re-
garded as a supplemental test. Another limitation is that
both screening and supplemental tests fail to detect infec-
tion during the immunologic window, in which antibodies
are either absent or present at very low concentrations. In
this case, only molecular tests are able to detect HCV
infection (9).
Thus, the laboratory diagnosis of HCV infection requires
more than one test (screening and supplemental) to confirm
a result, since a gold standard test is still unavailable. An-
other problem is the lack of standardization in interpreting
the results of supplemental tests. Furthermore, the high cost
involved reduces the accessibility of these procedures in low
budget laboratories. In this respect, there is a need for more
available and less expensive alternative methods for the
diagnosis of HCV infection.
In 2003, the CDC recommended two new algorithms
(termed here A and B) as an alternative approach to the
conventional algorithm C (8). Algorithm A is an option that
uses signal-to-cut-off (s/co) ratios for screening-test-positive
results to minimize the number of samples that require
supplemental testing. For each population the proportion of
IB-positive among screening-test-positive results increases
with increasing s/co ratio. Algorithm B requires polymer-
ase chain reaction (PCR) tests for all ELISA-positive or
-inconclusive samples, as well as IB tests for samples with
negative PCR results. Conventional algorithm C requires an
IB test for all ELISA-positive or -inconclusive samples.
The use of these new algorithms in the US population
has been helpful for simplifying HCV diagnosis and lower-
ing its cost (8). In Brazil, few data concerning diagnostic
performance (10) and cost (11) are available. With this in
mind, we compared the diagnostic performance and the
cost-benefit of the two new algorithms (A and B) with the
conventional (C) one in Brazilian blood donors who showed
positive or inconclusive anti-HCV results in screening tests.
Material and Methods
Samples
From September 1997 to December 1998, 197,637
blood donors at Fundação Pró-Sangue Hemocentro de
São Paulo were screened with anti-HCV tests. Positive or
inconclusive results were obtained for 1796 (0.91%) of the
samples. A total of 692 blood donors who were positive at
the time of donation returned to the Institution to repeat the
screening test (ELISA). Of these, 175 (25.3%) were ELISA-
negative and the 517 who remained positive (437) or
inconclusive (80) formed our series and were submitted to
supplemental tests for anti-HCV.
The donors were informed that their blood samples
would be used for research purposes and they all signed
the corresponding informed consent term. The study was
approved by the Faculdade de Ciências Farmacêuticas,
Universidade de São Paulo (Protocol No. 204/2003) and
the Ethics Committee of Fundação Pró-Sangue Hemocen-
tro de São Paulo (Protocol No. 08/2003).
Algorithms evaluated for the laboratory diagnosis of
HCV infection
The basic strategy of this study was to compare the
results obtained for our sample by a conventional algo-
rithm, designated here algorithm (C), with the new algo-
rithms A and B recommended by the CDC.
Algorithm A requires the establishment of a specific
level of s/co ratio to determine the need for reflex supple-
mental testing. For this purpose, the s/co ratios of each
sample tested by ELISA were stratified into 6 groups: ≥1
<2, ≥2 <3, ≥3 <4, ≥4 <5, ≥5 <6, ≥6. The s/co ratio chosen for
cut-off (cut-off ratio) corresponded to the ratio which had
the highest ≥95% concordance with positive results in the
IB test. The sample was positive when the result had an s/
co ratio higher than the cut-off ratio. When the ratio was
lower than the cut-off ratio, reflex testing (IB) was required.
The sample was considered true positive when IB was
positive.
For algorithm B, reflex testing by the supplemental
nucleic acid amplification test (NAT) was required for
samples that were positive or inconclusive in the screening
test. A sample was considered true positive when both
ELISA and PCR were positive. When PCR was negative IB
was carried out.
The most commonly used algorithm is C, which is
based on the use of supplemental serologic reflex testing
such as IB to confirm screening-test-positive results.
We evaluated the concordance of the results obtained
by each algorithm. Samples with indeterminate IB results
were further analyzed by PCR using an algorithm termed
here as expanded form.
Number of tests required to apply each algorithm
The first assessment estimated the number of tests
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required to implement each of the three algorithms in all
samples. To predict the cost estimate of each algorithm,
we multiplied the resulting figures by the cost of each test.
The same estimate can be performed for each algorithm in
its expanded form.
Costs were estimated as follows and do not include
personal time or additional equipment: US$4.07/sample
for ELISA; US$68.80/sample for IB, US$22.93/sample for
in-house PCR, or US$91.74/sample for commercially avail-
able PCR. These values were obtained from 7 Brazilian
commercial kit suppliers and the mean value was used as
a base for cost estimation and converted into US dollars.
Laboratory tests
Screening test. The HCV antibody test was performed
according to manufacturer instructions using third-genera-
tion ELISA kits from EMBRABIO (Hemobio® ELISA HCV
third generation, São Paulo, SP, Brazil), which detects
antibodies against recombinant antigenic proteins NS3
and NS5 and against synthetic peptides corresponding to
core and NS4 genes. The cut-off recommended by the
manufacturer was calculated by the average absorbance
of the positive controls plus the average absorbance of the
negative controls, dividing the total by 5. Samples with
absorbance above this cut-off were considered to be posi-
tive, samples with absorbance below it were considered
negative, and ±10% ranges around the cut-off were con-
sidered to be inconclusive. The s/co ratio referred to ab-
sorbance of the sample signal (s) divided by co. Samples
with s/co ratio higher than 1.0 were considered to be
reactive by this screening test.
Immunoblot. The confirmation of positive and inconclu-
sive ELISA anti-HCV test results was obtained using a
supplemental third-generation immunoblot kit (Immuno-
blot LiaTeK® HCVIII from Organon Teknika, Boxtel, Neth-
erlands) according to manufacturer instructions. The kit
contained protein fractions corresponding to the genomic
regions of core 1, core 2, E2NS1, NS3, NS4 (A and B), and
NS5A.
The reactive bands were read as scores, specifically
1+, 2+, 3+, and 4+, which were compared to the internal
control bands of the kit. Results were interpreted according
to literature references (12): positive when at least two
bands were ≥1+; negative when bands were absent and
indeterminate otherwise.
Samples were classified as serologically positive when
both ELISA and IB tests were positive.
Molecular tests
HCV RNA detection was performed in all serum
samples, which were stored at -20°C, using the nested
PCR in-house technique.
Extraction of RNA HCV and cDNA synthesis. RNA
isolation: 100 µL serum was mixed with 300 µL Trizol
(Gibco-BRL, Gaithersburg, MD, USA), and incubated for 5
min at room temperature. Eighty microliters chloroform
(Sigma, St. Louis, MO, USA) was then added. The mixture
was vigorously shaken, incubated at room temperature for
2 to 15 min, and centrifuged at 12,000 g for 15 min at 4°C.
The supernatant was transferred to a tube and RNA was
precipitated from the colorless aqueous phase with 40 µL
1 µg/µL dextran T500 (Amersham Pharmacia Biotech Inc.,
Piscataway, NJ, USA) and 200 µL isopropanol (Sigma).
The mixture was agitated briefly and incubated at room
temperature for 10 min, and centrifuged at 12,000 g for 10
min at 4°C. The pellet was washed in ice cold 70% ethanol
and centrifuged at 7500 g for 5 min. The supernatant was
removed and the RNA pellet was briefly air dried.
cDNA synthesis. The pellet was dissolved in 12 µL of a
solution containing diethyl pyrocarbonate-treated water
and 300 ng random primers (Pharmacia Biotech). After the
denaturation step at 70°C for 10 min, cDNA was synthe-
sized from RNA by the addition of a solution containing 100
U reverse transcriptase (SuperScript™ II Rnase H-Reverse
Transcriptase Gibco-BRL), 50 mM Tris-HCl, 75 mM KCl, 3
mM MgCl2, 10 µM DTT, 5 U Rnase inhibitor (Gibco-BRL),
and 0.5 mM 2'-deoxynucleoside 5'-triphosphate mix (dNTP;
Pharmacia Biotech), in a final reaction volume of 20 µL.
The mixture was incubated at 42°C for 90 min and then
heated at 70°C for 15 min.
Polymerase chain reaction amplification
A two-round PCR was run in a thermal cycle as follows:
initial cycle at 94°C for 1 min and 40 cycles at 94°C for 30
s, 55°C for 30 s, and 72°C for 30 s, followed by a final
extension-cycle at 72°C for 5 min. NCR1 (5'-GTATCTCGA
GGCGACACTCCACCATAG-3') and NCR2 (5'-ATACTCGA
GGTGCACGGTCTACGAGAC-3') were used as outer prim-
ers, and NCR3 (5'-CCACCATAGATCTCTCCCCTGT-3') and
NCR4 (5'-CACTCTCGAGCACCCTATCAGGCAGT-3') as
inner primers. For the first amplification round, 5 µL cDNA
was mixed with 45 µL of a reaction mixture containing 20
mM Tris-HCl, 50 mM KCl, 2 mM MgCl2, 0.15 mM dNTP
(Pharmacia Biotech) mix, 1 U Taq DNA polymerase (Gibco-
BRL), and 12.5 pmol of each outer primer. The second
amplification was performed using 3 µL of the first amplifi-
cation product and a mixture of the same composition as
described above, but using inner primers, 0.2 mM dNTP
(Pharmacia Biotech) mix and 1.5 mM MgCl2. The second
PCR amplification product was separated by 1.5% aga-
rose gel electrophoresis, stained with ethidium bromide
and visualized under ultraviolet light.
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The first PCR round amplified a fragment of the 5'-
untranslated region of the HCV genome with about 300 bp,
and the second round amplified an internal fragment of the
first amplification product of approximately 235 bp (13,14).
The test sensitivity was about 1000 copies/mL, as
determined by the control VQC serum panel (Viral Quality
Control Laboratory, Alkmaar, Netherlands) of the profi-
ciency program for viral NAT assays (15).
Commercially available polymerase chain reaction kits
A total of 38 samples reactive for both ELISA and IB but
negative for nested PCR were submitted to a commercially
available PCR test (Amplicor HCV version 2.0, Roche
Molecular Systems, Branchburg, NJ, USA). This PCR was
performed according to manufacturer instructions and com-
prised three major steps: RNA extraction, cDNA amplifica-
tion with biotinylated primers, and amplicon detection. The
internal control of known concentration was amplified simul-
taneously with the HCV RNA to ensure the validity of the test
reaction. The biotinylated amplicon product was detected by
hybridization with specific probes adsorbed on the micro-
plate surface. The test detection limit was 50 IU/mL.
Results
A global comparison of algorithms A, B and the con-
ventional algorithm (C) for the diagnosis of HCV infection is
given in Figure 1. The conventional algorithm (C) was able
to define the serological diagnosis in 72.7% of the samples
(285/517 as positive and 91/517 as negative results);
however, 27.3% (141/517) remained indeterminate.
For algorithm A the stratification of s/co ratio performed
in all 517 ELISA-positive samples resulted in the IB confir-
mation rates shown in Table 1.
Figure 1. Algorithms A, B or C required for the diagnosis of HCV infection in a Brazilian population. The present study compared the
conventional algorithm (C ) used in most laboratories with the two new algorithms (A and B) recommended by the Centers for Disease
Control and Prevention, USA. The three algorithms were applied to 517 ELISA-positive and -inconclusive serum samples of blood
donors from Fundação Pró-Sangue - Hemocentro de São Paulo, who had returned to the institution to confirm their previous results.
s/co = signal-to-cut-off.
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The use of algorithm A provided 287 positive results, in
which 238 samples had s/co ratio ≥6, while 49 had s/co
ratio <6 but positive by IB. Negative results were obtained
in 91 samples and indeterminate in 139. Therefore, algo-
rithm A was able to define serologic diagnosis in 73.1%
(378/517) of the samples, and 26.9% (139/517) remained
undefined (IB indeterminate). The concordance of positive
results obtained by algorithm A and by the conventional
algorithm C was 99.3% (285/287).
For algorithm B, 287 results were considered positive,
comprising 249 PCR-positive and 38 PCR-negative (in-
house and commercial PCR) but IB-positive tests. Nega-
tive results were obtained for 91 samples by both PCR and
IB tests, and 139 samples were PCR negative and IB
indeterminate. Thus, algorithm B defined a serological or
molecular diagnosis in 73.1% (378/517) of the samples.
Despite the indeterminate IB results, 26.9% (139/157) of
the samples were defined because PCR-negative results
allowed us to exclude possible active infection.
The concordance between algorithm B and conven-
Table 2. Serological and molecular results of the four samples whose results were in disagreement with algorithms A,
B, and C.
Sample ELISA-s/co ratio Immunoblot PCR Algorithm result
A B C
86 8.6 Indeterminate Negative Positive Indeterminate Indeterminate
2268 7.0 Indeterminate Negative Positive Indeterminate Indeterminate
1992* 1.0 Indeterminate Positive Indeterminate Positive Indeterminate
2699** 4.3 Indeterminate Positive Indeterminate Positive Indeterminate
s/co = signal-to-cut-off; cut-off ratio = s/co ratio with ≥95% concordance with IB-positive results. *The initial sample,
31 days before the confirmation sample, showed s/co ratio = 1.0 as determined with the Embrabio kit (Hemobio®
ELISA HCV third generation, São Paulo, SP, Brazil). However, it was positive when tested with the Murex-Abbott kit
(s/co ratio >4.0); **Initial sample, 2 months before the confirmation test that showed the s/co ratio = 1.6 (possible
window period).
tional algorithm C was 99.3% (285/287).
The positive results obtained using the three algo-
rithms were: 287 for algorithm A, 287 for B, and 285 for
conventional algorithm C. However, some of the samples
did not receive a definite diagnosis owing to indeterminate
IB results.
A total of 283 samples were positive for all three algo-
rithms. Discrepant results were observed in four samples.
Two of them were only positive for algorithm A (samples
2268 and 86, with s/co ratio ≥6) and the other two were only
positive for algorithm B (samples 1992 and 2699, PCR-
positive). All four samples were indeterminate for the con-
ventional algorithm (C; Table 2).
The cost of each algorithm depends on the method
used and on the number of tests performed. The number
and the cost of ELISA, IB and PCR tests performed for
algorithms A, B and conventional C are shown in Table 3.
The cost of algorithms A and B (in-house PCR) were 43.5
and 14.0%, respectively, lower than the cost of C; the cost
of algorithm B using a commercial PCR kit was 80.4%
Table 1. Association of the signal-to-cut-off (s/co) ratio obtained in all of the 495 ELISA-positive results, stratified into
six groups, with the frequency of positive results obtained by anti-HCV immunoblot (IB) or by in-house nested PCR, or
both.
ELISA-s/co ratio IB positive PCR positive IB and PCR positive
≥1<2 (164) 4.9% (8/164) 0.6% (1/164) 0.0% (0/164)
≥2<3 (29) 13.8% (4/29) 0.0% (0/29) 0.0% (0/29)
≥3<4 (22) 36.4% (8/22) 13.6% (3/22) 13.6% (3/22)
≥4<5 (29) 65.5% (19/29) 51.7% (15/29) 48.3% (14/29)
≥5<6 (13) 76.9% (10/13) 46.2% (6/13) 46.2% (6/13)
≥6 (238) 99.2% (236/238) 94.1% (224/238) 94.1% (224/238)
Determination of the cut-off ratio = s/co ratio value with ≥95% concordance with IB-positive results. Twenty-two
ELISA-inconclusive samples (s/co ratios ≥0.9 and <1) and negative by IB and PCR are not shown in this table.
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higher than the cost of C.
In order to clarify indeterminate results (139 by algo-
rithm A and 141 by algorithm C), these algorithms were
expanded by performing PCR, with two samples becoming
positive by this procedure. The total number of tests per-
formed for each method, the cost involved in expanding
the algorithms and the comparison among their cost can
be seen in Table 4. The cost of algorithms A and C
increased by 15.0 and 8.6%, respectively, when the algo-
rithms were expanded using in-house PCR and by 59.1
and 34.3% if a commercial PCR was used. When using in-
house PCR, the expanded algorithm A was 40.1% cheaper
than the expanded algorithm C and 32.7% less expensive
than when commercial PCR was used.
Discussion
Some laboratories report a result as positive for HCV
infection considering only the screening antibody test,
without any further confirmation by supplemental tests
such as IB or PCR (8). Since there is no established gold
standard test, and given the high cost of supplemental
tests for diagnosing HCV infection, the CDC published
guidelines that proposed the two new algorithms (termed A
and B in the present study) as an alternative to the conven-
tional one.
In the present study, for algorithm A, the cut-off ratio ≥6
for ELISA-positive samples agreed with IB-positive results
in 99.2% of the cases, underscoring its ability to accurately
predict true antibody-positive results.
Some investigators have also considered s/co ratio as
an effective viremia predictor. In samples with strong ELISA-
positive results (s/co ratio >50) HCV RNA was detected in
93.6% of the cases. These investigators suggested a
threshold set at s/co ratio = 10 to separate viremic and non-
viremic populations (12). The cut-off ratio may vary ac-
cording to the kit manufacturer and to the population
tested, so it must be carefully established for each labora-
tory. Reports from the US CDC show that average s/co
ratio >3.8 is highly predictive of the true anti-HCV status for
Table 4. Number of ELISA, immunoblot, or in-house PCR tests required for 517 samples to implement
expanded algorithms A or C.
Confirmatory test Expanded algorithm A Expanded algorithm C
In-house PCR (US$22.93)* $3,187.27 (139) $3,233.13 (141)
Total cost of algorithms A andC (shown in Table 3) $21,299.39 $37,673.79
Total cost for 517 samples $24,486.66 $40,906.92
Data are reported in US dollars with number of tests in parentheses. *The cost of PCR using a
commercially available kit (Amplicor® Hepatitis C virus test, version 2.0, Roche, Branchburg, NJ, USA)
was US$91.74 per sample tested. For all 517 samples the total cost for the expanded algorithm A was
US$34,051.25, and for the expanded algorithm C it was US$50,609.13.
Table 3. Number of ELISA, immunoblot, or PCR tests required for 517 samples and the estimated cost to
implement algorithms A, B or C.
Algorithm A Algorithm B Algorithm C
ELISA (US$4.07) $2,104.19 (517) $2,104.19 (517) $2,104.19 (517)
Immunoblot (US$68.80) $19,195.20 (279) $18,438.40 (268) $35,569.60 (517)
In-house PCR (US$22.93)* 0 $11,854.81 (517) 0
Total cost for 517 samples $21,299.39 $32,397.40 $37,673.79
Data are reported in US dollars with number of tests in parentheses. *In algorithm B, the cost of PCR
using a commercially available kit (Amplicor® Hepatitis C virus test, version 2.0, Roche, Branchburg, NJ,
USA) was US$91.74 per sample tested. For all 517 samples the total cost was US$67,972.17.
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kits manufactured by Ortho-Clinical Diagnostics (Ortho
HCV version 3.0 ELISA, Raritan, NJ, USA) and by Abbott
EIA (Abbott EIA 2.0, Chicago, IL, USA) and ratios >8.0 for
kits manufactured by VITROS anti-HCV (Ortho-Clinical
Diagnostics) (16,17), with sensitivity higher than 95%. A
wide range of variation has been reported by Ren et al. (18)
for domestic EIA kits, such as 6.0 to 14.0, with ≥95%
sensitivity. Reflex supplemental testing could be limited to
screening test-positive samples with ratios below the cut-
off value. In studies conducted in October 2000 using the
second-generation HCV ELISA assay, the authors ob-
tained s/co ratio >3.0 as cut-off and high concordance
(96%) with IB-positive tests (10).
In our samples, algorithm A was able to diagnose 46%
(238/517) of the samples as true positive only by ELISA (s/
co ratio ≥6). In 54% (279/517) of the cases with s/co ratio
<6 the IB tests were performed, producing definite positive
(N = 49) or negative (N = 91) results in almost half the
samples (140/279). For the remaining 139 (26.9%) samples,
algorithm A was unable to define a laboratory diagnosis
because of the indeterminate IB results.
Algorithm A was considered to be the best in terms of
cost and feasibility, and for minimizing the number of
samples requiring supplemental testing, being particularly
suitable for limited resource laboratories. However, supple-
mental PCR tests were still required to detect active infec-
tion.
For algorithm B, all 517 ELISA-positive samples were
submitted to reflex PCR testing, which produced positive
results in 48.2% (249/517) of the cases. IB tests were
carried out for the remaining 51.8% (268/517) of PCR-
negative samples. No conclusive diagnosis was obtained
for 139 (26.9%) samples (indeterminate IB). Nevertheless,
the PCR-negative results for these samples were sufficient
to define diagnosis, showing the absence of viremia, which
is important in clinical practice.
The conventional algorithm (C) is particularly important
in low prevalence populations, especially prone to false-
positive HCV infection results. However, infection activity
cannot be confirmed using only IB testing. The IB test used
for this algorithm resulted in 141 (27.3%) indeterminate
results, similar to the rate obtained using algorithm A,
providing no conclusive diagnosis.
All three algorithms had similar diagnostic performance
for the samples studied. Positive results were obtained in
287, 287 and 285 cases for algorithms A, B, and C,
respectively. These data revealed a remarkable agree-
ment in the results obtained by the algorithms.
PCR was performed to clarify indeterminate results
(139 samples from algorithm A and 141 samples from
conventional algorithm C) and was also applied to samples
from the three algorithms that did not agree. This supple-
mental diagnosis entailed increased cost and is not man-
dated by the CDC.
The main problem related to IB testing concerns the
indeterminate results. Some plausible causes are: 1) sero-
conversion phase, during which ELISA is already positive
due to its higher sensitivity when compared to the IB test,
which can still fail to meet the positivity criteria (19,20); 2)
seroreversion in patients who spontaneously eliminate
HCV. In these individuals, antibodies against some anti-
genic fractions have already turned negative for the IB test,
but they are sufficient to yield ELISA-positive results (19,21);
3) individuals infected with genotype 3 or other uncommon
genotypes that could have low reactivity to antigen frac-
tions from genotype 1a used in most commercially avail-
able kits for anti-HCV. In this case, IB may be indetermi-
nate but ELISA could be positive due to the reaction with
better-preserved antigens such as core (22). 4) Other
factors related to the kit performance (23) or to patient
immunoresponse variability (24) may be involved.
Two samples (2699 and 1992) were PCR positive for
algorithm B, but were indeterminate for both algorithm A
and C. Sample 2699 had an s/co ratio three times higher in
the sample collected at the donor’s return visit when com-
pared to that collected at the time of donation. This sug-
gests that the sample belonged to an individual who was
under seroconversion. IB was indeterminate in the pres-
ence of an NS3 band. This band was supposedly the one
that most favors early seroconversion detection. It also
shows concordance with viremia (25), which is consistent
with the hypothesis we proposed. Sample 1992 had an s/
co ratio of 1.0 and was IB indeterminate, with bands NS3
(±), NS5 (±) and NS4 (2+). A sample collected 31 days
before the patient’s return visit also had an s/co ratio of 1.0,
indicating the low probability of its corresponding to a
seroconversion phase, because the antibody level de-
tected by ELISA did not increase during the period be-
tween the two sample collections. However, this same
sample was ELISA positive upon further testing using a kit
from a different manufacturer (Murex, Abbott Laborato-
ries), showing s/co ratio >4.0, suggesting low reactivity of
the ELISA kit initially used. The positive PCR result en-
sured that the sample belonged to a patient truly infected
by HCV.
Samples 2268 and 86 were positive only for algorithm
A owing to their s/co ratios of 7.0 and 8.6, respectively.
Both were IB indeterminate and PCR negative. These
results could correspond to individuals who had spontane-
ously eliminated the virus and who were in the early
seroreversion phase (19,26-28). However, the possibility
of false-positive ELISA results must also be considered.
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The cost of each algorithm depends on the number of
supplemental tests required and varies according to the
frequency of positive results in the population studied. It
can be estimated by multiplying each test by its unitary cost
(11) that was estimated taking into account the selling
price used in Brazil; however, it must be only considered as
an example. The following supplemental tests were car-
ried out for the 517 ELISA-positive samples: 279 IB tests
for algorithm A; 517 PCR and 268 IB tests for algorithm B,
and 517 IB tests for conventional algorithm C. The total
cost of the algorithms in American dollars on August 2007
based on the mean cost of 7 commercial tests (ELISA, and
IB) and in-house PCR showed that algorithms A and B
were respectively 43.5 and 16.0% cheaper than C. How-
ever, if the commercial PCR is used, the total cost of
algorithm B will be 80.4% higher than the cost of algorithm
C. Algorithm A was certainly the most economical option
while the cost of algorithms B and C depends on the use of
either in-house PCR or a commercially available kit.
In order to solve the problem of indeterminate IB re-
sults, algorithms A and C were expanded by performing in-
house PCR testing which detected two additional positive
samples. Algorithms A and C became 15.0 and 8.6% more
expensive when they were expanded. Therefore, the cost
of expanded algorithm A was 40.1% lower than that of
expanded algorithm C that required lower number. In labo-
ratories using the commercially available PCR kit, the cost
of algorithms A and C increased significantly for a total of
517 samples (US$34,051.25 and US$50,609.13, respec-
tively) but is lower than algorithm B (US$67,972.17). The
expanded algorithm A involved the lowest number of supple-
mental tests, which are very expensive.
Algorithm A is also recommended for populations with
a high prevalence of HCV infection owing to its consistently
positive results in screening tests and high concordance
with true-positive results, in that IB testing was required
only for weakly reactive samples (3). With respect to algo-
rithm B, PCR performance may speed up the clinical
decision and lead to early treatment of HCV infection. This
algorithm is the most suitable for immunosuppressed pa-
tients for whom the IB test could represent a problem
because of its low antibody level, leading to occasional
false-negative results. Conventional algorithm C was use-
ful for determining the immune status of the patients against
HCV infection and also for confirming the specificity of
positive ELISA results. It is recommended for low preva-
lence populations for which false-positive antibody results
are usually high. However, in the present study, this algo-
rithm yielded a high frequency of IB-indeterminate results,
producing no conclusive diagnosis. Furthermore, this al-
gorithm did not differentiate between active and past infec-
tions, a fact that may be crucial for clinical purposes.
Since screening tests are currently performed using
only serological tests, of the three alternatives, algorithm B
provided the most complete information. However, it was
unable to screen pre-seroconversion phase individuals
because ELISA-negative samples (a condition observed
during the window phase) were not submitted to PCR.
The mandatory application of the NAT would render
the IB test unnecessary except for ELISA-positive and
NAT-negative samples. In this case, the IB test would
screen patients with past HCV infections who have sponta-
neously eliminated the virus.
The new algorithms A and B are highly sensitive and
could be validated to diagnose HCV infection in Brazil. The
choice of an algorithm must take into account its purpose,
the population and the prevalence of HCV infection. It
would also depend on the financial and infrastructure
conditions of the laboratory.
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